Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cardiol Therapeutics ( (TSE:CRDL) ) just unveiled an announcement.
On October 21, 2025, Cardiol Therapeutics announced the completion of a US$11.4 million financing, extending their cash runway into the third quarter of 2027. This funding supports the MAVERIC Phase III trial for CardiolRx™ in recurrent pericarditis and the development of CRD-38 for heart failure. The ARCHER trial results, showing significant reduction in left ventricular mass, bolster the potential of CardiolRx™ and CRD-38 in addressing heart failure, a condition with high mortality rates. The company’s strategic advancements position it to meet significant unmet needs in heart disease treatment.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$8.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on TSE:CRDL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Underperform.
Cardiol Therapeutics faces substantial financial challenges, primarily driven by ongoing losses and negative cash flow. The stock’s technical indicators suggest mixed momentum, and its valuation is constrained by a negative P/E ratio. However, promising clinical developments and strategic advancements in heart disease treatments provide some positive outlook, though these are not sufficient to offset the financial and technical concerns.
To see Spark’s full report on TSE:CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Their lead drug candidate, CardiolRx™, targets inflammasome pathway activation, which is significant in the progression of inflammation and fibrosis in conditions like pericarditis, myocarditis, and heart failure. The company is also advancing CRD-38, a next-generation therapy for heart failure.
Average Trading Volume: 169,189
Technical Sentiment Signal: Sell
Current Market Cap: C$125.6M
See more data about CRDL stock on TipRanks’ Stock Analysis page.